Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paclitaxel AND Pemetrexed

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Paclitaxel AND Pemetrexed. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-003372-39 Sponsor Protocol Number: INCMGA0012-304 Start Date*: 2020-06-21
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
    Medical condition: Male and female participants at least 18 years of age (or as per adult age applicable per local country requirements) who have metastatic nonsquamous or squamous NSCLC.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080083 Advanced lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003474-35 Sponsor Protocol Number: 16-214-05 Start Date*: 2020-02-13
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab with or without Chemotherapy in Patients wit...
    Medical condition: Patients with with locally advanced or metastatic solid tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001547-32 Sponsor Protocol Number: CACZ885U2301 Start Date*: 2018-12-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first lin...
    Medical condition: stages AJCC v. 8 IIIB/IIIC (not eligible for definite chemoradiation therapy) or stage IV (metastatic) non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Completed) GR (Completed) ES (Ongoing) IS (Completed) SK (Completed) AT (Completed) PT (Completed) DK (Completed) FI (Completed) SE (Completed) HU (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014563-39 Sponsor Protocol Number: 1200.42 Start Date*: 2010-03-02
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versus Investigator’s choice of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous...
    Medical condition: Patients with NSCLC stage IIIb and IV after failure of treatment with erlotinib or gefitinib
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) BE (Completed) FI (Completed) GB (Completed) HU (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006044-27 Sponsor Protocol Number: IFCT-2103 Start Date*: 2022-02-10
    Sponsor Name:IFCT
    Full Title: A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pe...
    Medical condition: Advanced Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000262-38 Sponsor Protocol Number: CA209-77T Start Date*: 2019-08-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolum...
    Medical condition: Resectable Stage II-IIIB Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002718-32 Sponsor Protocol Number: CanStem43L Start Date*: 2017-04-04
    Sponsor Name:Boston Biomedical, Inc.
    Full Title: A Phase III Randomized, Open-Label Clinical Trial of BBI-608 plus Weekly Paclitaxel versus Weekly Paclitaxel Alone in Patients with Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Ca...
    Medical condition: Histologically or cytologically confirmed recurrent, locally advanced, or metastatic non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10066490 Progression of non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004606-21 Sponsor Protocol Number: D926NC00001 Start Date*: 2022-10-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-...
    Medical condition: NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001473-14 Sponsor Protocol Number: MK-3475-042 Start Date*: 2014-10-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metast...
    Medical condition: Non-Small Cell Lung Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) LT (Completed) LV (Completed) PT (Completed) PL (Completed) EE (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-001170-32 Sponsor Protocol Number: H3E-MC-JMIG Start Date*: 2008-09-05
    Sponsor Name:Eli Lilly and Company limited
    Full Title: Protocol H3E-MC-JMIG Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytoto...
    Medical condition: patients with locally advanced, unresectable/inoperable, Stage III, nonsquamous NSCLC without malignant pleural/pericardial effusion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) ES (Completed) NL (Completed) BE (Completed) FR (Completed) DE (Completed) GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003719-23 Sponsor Protocol Number: CA209-9TN Start Date*: 2020-02-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention with Adjuvant Nivolumab in Non- Small Cell Lung Cancer Participants with ctDNA detected Minimal Residual Disease after Surgical ...
    Medical condition: Non-Small Cell Lung Cancer with ctDNA detected Minimal Residual Disease after Surgical Resection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003121-34 Sponsor Protocol Number: NVALT22 Start Date*: 2016-03-21
    Sponsor Name:Stichting NVALT studies
    Full Title: Chemotherapy in KRAS mutated chemotherapy naive non-small cell lung cancer patients: a phase III study comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22
    Medical condition: Advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004397-34 Sponsor Protocol Number: D933KC00001 Start Date*: 2018-05-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Adv...
    Medical condition: Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001810-27 Sponsor Protocol Number: MK-3475-715(INCB024360-306) Start Date*: 2017-12-15
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Pl...
    Medical condition: First-line treatment of metastatic NSCLC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) DE (Prematurely Ended) HU (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001195-35 Sponsor Protocol Number: CA209-9LA Start Date*: 2017-09-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: Stage IV Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004026-31 Sponsor Protocol Number: CA224-104 Start Date*: 2021-03-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Re...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) AT (Completed) NL (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000027-12 Sponsor Protocol Number: IJB-IRAES-2020 Start Date*: 2022-06-26
    Sponsor Name:Institut Jules Bordet
    Full Title: Immunological variables associated to ICI toxicity in cancer patients IRAES
    Medical condition: solid tumour
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002425-52 Sponsor Protocol Number: H3E-MC-JMEN(a) Start Date*: 2005-03-24
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 3 Study of Pemetrexed Plus Best Supportive Care versus Best Supportive Care As Maintenance Therapy Immediately Following Induction Treatment For Advanced Non-Small Cell Lung Cancer
    Medical condition: Non Small Cell Lung Cancer Stage IIIB or Stage IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003719-42 Sponsor Protocol Number: GO27821 Start Date*: 2012-05-29
    Sponsor Name:Genentech Inc.
    Full Title: A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB + PLATINUM + PACLITAXEL OR PEMETREXED...
    Medical condition: MET DIAGNOSTIC−POSITIVE NON−SMALL CELL LUNG CANCER (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10025054 Lung cancer non-small cell stage IIIB LLT
    16.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    16.0 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005331-78 Sponsor Protocol Number: ACT16849 Start Date*: 2022-09-06
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Phase 2 non-randomized, open-label, multi-cohort, multi center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participa...
    Medical condition: Pleural mesothelioma Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 22:07:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA